Su Xia Luo

  • Citations Per Year
Learn More
BACKGROUND  : Phase II-III trials in patients with untreated and previously treated locally advanced or non-small cell lung cancer (NSCLC) suggested that Endostar was able to enhance the effect of(More)
  • 1